Skip to main content
Premium Trial:

Request an Annual Quote

NextGen and Kemp Ink Protein Co-Marketing Pact

NEW YORK (GenomeWeb News) — NextGen and Kemp Biotechnologies will co-market their fee-for-service offerings, NextGen said today.
 
UK-based NextGen is a so-called “gene-to-protein” company, whereas Kemp provides expertise in cell culture, protein expression, and protein purification services.
 
Under the agreement, NextGen will offer Kemp’s pure proteins for pre-clinical research.
 
NextGen said the alliance will offer soluble active proteins that have been derived from gene sequences that are associated with disease in milligram to multi-gram quantities for structure determination, screening, characterization, or pre-clinical research studies.
 
Kemp also will transfer its transient mammalian expression technology to NextGen, which the company said will add to the range of protein-expression systems it already offers.
 
Financial terms of the agreement were not released.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.